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Cardiovascular diseases are a worldwide health problem and are the leading cause of mortality in developed countries. Together
with experimental data, the lower incidence of cardiovascular diseases in women than in men of reproductive age points to the
influence of sex hormones at the cardiovascular level and suggests that estrogens play a protective role against cardiovascular
disease and that this role is also modified by ageing. Estrogens affect cardiovascular function via their specific estrogen receptors
to trigger gene expression changes at the transcriptional level. In addition, emerging studies have proposed a role for
microRNAs in the vascular effects mediated by estrogens. miRNAs regulate gene expression by repressing translational
processes and have been estimated to be involved in the regulation of approximately 30% of all protein-coding genes in
mammals. In this review, we highlight the current knowledge of the role of estrogen-sensitive miRNAs, their influence in
regulating vascular ageing.1. Introduction
The prevalence, incidence, and prognosis of cardiovascular
diseases differ between genders. Indeed, statistical data reveal
that women develop cardiovascular disease later than men
[1] and the incidence of cardiovascular diseases in women
increases from menopause [2, 3]. Both clinical and experi-
mental data have extensively demonstrated the beneficial
effects of estrogens at the cardiovascular level [4, 5], although
hormonal replacement therapies (HRTs) in postmenopausal
women have been implemented with controversial results [6,
7]. Such studies have led some researchers to conclude that
the protective effect of HRT depends on age [8].
Ageing is a physiological and multifactorial process char-
acterized by the progressive loss of anatomical and functional
integrity, which leads to an increased risk of different pathol-
ogies, including cardiovascular disease. At the molecular
level, different mechanisms have been established as crucial
in the regulation of the ageing process [9]. Among these,epigenetic mechanisms affect gene expression without caus-
ing changes in the DNA sequence and can be influenced by
external factors, including the environment and lifestyle [10].
Some evidence indicates that estrogen-dependent regula-
tion of cardiovascular function in ageing is mediated by epi-
genetic mechanisms. An age-related increase in methylation-
associated inactivation of genes encoding estrogen receptors
(ERs) has been described, and ER methylation in atheroscle-
rotic plaques is higher than in nonplaque regions in vascular
tissues [11, 12], which suggests that estrogen activity in ath-
erogenesis and vascular system aging is epigenetically regu-
lated. Another epigenetic mechanism that has also been
associated with estrogens is histone modification. In this
regard, in a postmenopausal metabolic syndrome murine
model, estradiol prevented cardiovascular dysfunction by
suppressing histone H3 acetylation [13].
In addition to DNA methylation and histone modifica-
tion, the most recently described epigenetic mechanism is
RNA-based machinery. Regulatory noncoding RNAs are
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microRNAs (miRNAs) constitute the dominant class in most
tissues. MiRNAs regulate protein translation by targeting
their target messenger RNAs (mRNAs) via sequence-
specific interaction to repress translation or degrade target
mRNA [14]. In addition, emerging evidence suggests that
miRNAs have also nuclear functions in the regulation of gene
expression at transcriptional level [15]. Most miRNAs are
located within cells, although some have also been found
circulating in body fluids [16]. Thus, miRNA-mediated regu-
lation is now considered one of the most important posttran-
scriptional gene regulation mechanisms and is estimated to
modulate up to 30% of mammal genes, including important
roles in human physiology, ageing, and cardiovascular func-
tion [17, 18].
Given the world’s increasingly ageing population [19]
and that cardiovascular diseases are the leading cause of
death in developed countries, it is important to improve
our understanding of the regulatory mechanisms underlying
the ageing of the cardiovascular system. In addition, although
growing evidence has established miRNAs as crucial epige-
netic regulators of vascular function, their role in the regula-
tion of estrogen in cardiovascular ageing has not yet been
fully elucidated. Therefore, in this review, we summarize cur-
rent knowledge of the role of estrogens in cardiovascular
function and ageing with a special focus on the miRNAs
related to estrogens during female vascular ageing.
2. The Involvement of Estrogens in
Vascular Function
Estrogens modulate the cardiovascular system directly by
acting on vascular and inflammatory cells, which express
ERs, or indirectly via systemic effects [20]; estrogen functions
through ERs by genomic and nongenomic mechanisms. In
the former, also known as the “classical” mechanism, estro-
gens bind to ERs to form a complex that regulates gene tran-
scription by binding to specific DNA motifs in gene
promoter regions [21]. In this sense, ERα and ERβ are the
two main ER isoforms, and these form homo- or heterodi-
mers, which can induce changes in gene expression. The
involvement of specific ER isoforms in estrogen-mediated
effects has been extensively studied [22], and both opposing
gene expression regulatory effects [23, 24] and redundant
mediatory roles [25, 26] have been described. Estrogen sig-
naling is selectively regulated by the relative balance between
ERα and ERβ expression in target organs [27], although the
beneficial effects that estrogens have on the vascular system
are mainly attributed to ERα [28, 29]. Furthermore, estrogens
can also trigger fast responses through plasma membrane ER
receptors and G protein-coupled ERs (GPERs) [30].
In general, the vascular protective effects of estrogens are
attributed to their role in increasing arterial vasodilation,
their action on vasoactive mediator release and smooth mus-
cle contraction, inhibition of inflammatory processes, and
regulation of systemic lipid metabolism and oxidative stress
balance [2, 31, 32]. The regulation of vascular reactivity by
estrogens is mainly related to the maintenance of normal
endothelial function [33]. In endothelial cells, estrogensmodulate nitric oxide (NO) bioavailability by both genomic
and nongenomic effects by increasing endothelial NO syn-
thase (eNOS) expression at the transcriptional level, eNOS
activation through phosphorylation, and regulation of its
endogenous inhibitors and cellular location [34–36]. More-
over, a role for estrogens in regulating other vascular media-
tors related to prostanoids and endothelin signaling has also
been described. Estradiol increases prostacyclin release by
upregulating cyclooxygenase 1 (COX-1) and prostacyclin
synthase (PGIS) expression in endothelial cells [37] and by
decreasing endothelin-1 release in both basal and stimulated
conditions [38, 39].
In addition to the regulation of endothelial-derived
factors, estrogens directly regulate the smooth muscle layer
by inhibiting the proliferation, migration, and vascular con-
traction of vascular smooth muscle cells (VSMCs) [40].
Indeed, estrogen-mediated vasorelaxation can also occur in
endothelium-denuded segments [41]. Specifically, estradiol
decreases smooth muscle constriction by interfering in the
mechanisms of Ca2+ mobilization and Ca2+ entry [42] and
by activating K+ channels [43], leading to membrane hyper-
polarization and vascular relaxation. Estrogen can also mod-
ulate vasoconstriction by interfering in protein kinase C and
Rho-kinase signaling in VSMCs [44, 45].
The renin-angiotensin system (RAS) is another impor-
tant regulator of vascular contractibility which is regulated
by estrogen. Estrogens are implicated in the inhibition of
circulating renin, the activity of angiotensin-converting
enzymes, and in circulating angiotensin (Ang) II levels [46].
Furthermore, components of RAS are synthesized and act
locally in different tissues, including in the vasculature. In this
case, estradiol increases the expression of Ang 1–7 by induc-
ing the expression of angiotensin-converting enzymes [47]
and of Ang II receptor type 1 expression [48] in endothelial
cells, thus promoting vasodilation. In addition, estradiol-
dependent NO production is mediated by Ang 1–7-induced
activation of the Mas receptor [49], suggesting the presence
of a functional interaction between both these pathways.
The beneficial effects of estrogens in the cardiovascular
system are also attributed to their role in modulating the
inflammatory response [50] and vascular lipid accumulation
[32]. Estrogens inhibit monocyte-endothelial interactions by
reducing the expression of cell adhesion molecules in the
endothelium when exposed to inflammatory stimuli [51, 52].
Moreover, a reduction in neutrophil chemotaxis [53] and
leukocyte infiltration [54] have been established as inflam-
matory regulatory mechanisms which are mediated by
estrogens after vascular injury. Estradiol also reduces the
expression of superoxide-induced adhesion molecules and
cytokines in VSMCs by inhibiting nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase expression [55].
Moreover, it regulates oxidative stress by decreasing both
the expression and activity of superoxide dismutase in
VSMCs [56] and endothelial cells [57]. Estrogens can also
confer protective effects by modulating systemic lipid
metabolism [32], lipid-vascular wall interactions by reduc-
ing lipid loading [58, 59], and oxidative stress-mediated
LDL modifications [60], thus preventing the formation of
foam cells.
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Epidemiological data reveal sex differences in the number of
deaths caused by cardiovascular disease. These numbers are
greater in men than in women under the age of 65 and sim-
ilar over this age [61], suggesting the importance of ageing in
sex-related differences observed in cardiovascular disease. In
this regard, sex-specific differences of cardiovascular ageing
have been reported, and these patterns have been explained
by both hormonal and nonhormonal factors [62].
Considering the beneficial role of estrogens in the cardio-
vascular systems described above, the use of HRT in post-
menopausal women has produced controversial results [6,
7]. The current consensus indicates that the protective effects
that estrogens confer on cardiovascular function depend on
the prompt initiation of estrogen therapy after menopause
[63]. The phenomenon is referred to as the “timing hypoth-
esis” and postulates that estrogen supplementation may only
have beneficial effects when initiated before the detrimental
effects that ageing has on the cardiovascular system become
established [8]. Vascular ageing is associated with endothelial
dysfunction and arterial stiffening, vascular remodeling, and
increased inflammation [64]. These characteristics can lead
to pathological conditions such as myocardial hypertrophy,
fibrotic tissue formation, and increased systolic pressure,
resulting in a higher risk of atherosclerosis, hypertension,
and ischemic cardiovascular disease [65]. Endothelial dys-
function is less prominent in premenopausal women com-
pared to age-matched men and postmenopausal women,
which highlights the protective effect of estrogens [66].
Indeed, in a recent study, Nicholson et al. demonstrated that
the contractility responses of uterine arteries to estradiol
treatment in postmenopausal women were impaired com-
pared to their premenopausal counterparts [67].
The vascular ageing process is associated with a decline
in endothelial-dependent relaxation and an increased vaso-
constrictor responses mediated by an imbalance between
vasodilator and vasoconstriction factors [68–70]. In this
regard, NO and prostanoids seem to be the main pathways
implicated, and these act by progressively reducing the bio-
availability of NO and increasing vasoconstrictor prosta-
noids in aged vascular tissues. Indeed, relaxation induced
by bradykinin in isolated mesenteric microvessels was
mainly mediated by the action of NO, although COX-
dependent vasodilators were also implicated in young sub-
jects, whereas COX-dependent activity produced vasocon-
striction in older subjects [69]. Although some of the data
regarding eNOS expression at the molecular level are contra-
dictory, ageing progressively decreases eNOS activity both in
animal models and in human samples [71, 72]. Moreover,
decreased expression of the eNOS cofactor, tetrahydrobiop-
terin [73], elevated circulating levels of endogenous inhibi-
tors [74], and enhanced oxidative stress [69] have also been
postulated as mechanisms which underlie decreased eNOS
activity during ageing. Conversely, rather than altered
expression of the COX isoforms, an age-associated switch
from vasodilatory to vasoconstrictor prostanoid release has
been related to enhanced expression of the thromboxane
A2 (TXA2) receptor in the smooth muscle layer in bothhuman mesenteric arteries and in aortic segments from
female mice [69, 70, 75].
Oxidative stress is also increased in aged tissues, includ-
ing the vascular system, and influences endothelial dysfunc-
tion by scavenging NO, thus decreasing its bioavailability
[76]. Increased oxidative stress levels in vascular ageing are
caused by altered antioxidant enzyme expression and
enhanced production of reactive oxygen species (ROS)
mainly by mitochondria and NADPH oxidase but also by
COX and uncoupled eNOS [77]. The role of estrogens in oxi-
dative stress during ageing has been previously reported: in
vascular tissues, a decline in NO-mediated vasodilation is
associated with increased ROS, especially superoxide, in cor-
onary arterioles [78]. In the same study, the authors describe
a decrease in Cu/Zn superoxide dismutase expression in both
aged and ovariectomized rats, while estrogen replacement
restores its expression to the levels of young intact animals
[78]. Furthermore, COX-dependent superoxide production
induced by a TXA2 analogue in female aortic segments was
enhanced by ageing and estrogen deprivation, findings that
were abrogated by estrogen supplementation [79].
Ageing also influences the structural properties of vascu-
lature, and changes in the media thickness and extracellular
fiber content contribute to low arterial compliance. Specifi-
cally, ageing is associated with the increased production of
collagen fibers and decreased elastin fiber synthesis, vascular
calcification, and VSMC proliferation [80]. Estrogen admin-
istration mitigates progressive age-dependent reductions
both in human carotid artery wall thickness in postmeno-
pausal women [81] and in the mesenteric arteries of old
female rats [82]. In addition, increased collagen content has
been associated with decreased activity and protein levels of
specific collagen-degrading metalloproteinase enzymes [82,
83]. Finally, aberrant VSMC growth is also associated with
ageing-associated remodeling processes as VSMCs switch
from a contractile to synthetic-proliferative phenotype [84].
As previously described, estrogens inhibit the proliferation
of cultured VSMCs [40] and it is thought that ageing males
are more prone than females to these changes in the VSMC
phenotype [85]. In addition, estrogen treatment also attenu-
ates neointimal formation after vascular damage [86].
Finally, in relation to these metalloproteinase and VSMC
phenotypes, estrogens may be involved in plaque instability
and thus the greater cardiovascular disease risk in postmeno-
pausal women who start HRT late.
Along with endothelial dysfunction and vascular remod-
eling, the other key player in vascular ageing is inflammation.
Ageing is associated to a progressive increment of the tissue’s
proinflammatory status, phenomenon termed as “inflamma-
geing.” The signaling of this low-grade chronic inflammation
state is linked to an increased cell death, a metabolic dysfunc-
tion and a proteostasis loss, and it is also associated with an
age-related functional detriment [87]. At vascular level, the
ageing process is characterized by an acquisition of a proin-
flammatory phenotype with increased release of cytokines
and enhanced cell adhesion molecules expression, develop-
ing a more adhesive endothelium, phenomenon also known
as endothelial activation [64, 88]. The role of estrogens as
an anti- and/or proinflammatory factor in this process is
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cell types involved in the response, organ target, timing and
concentration of their administration, intracellular metabo-
lism of estrogen, and relative expression of the implicated
ERs [50]. In a study using uterine arteries from postmeno-
pausal women that were exposed to estradiol, Novella et al.
demonstrated that although estradiol exposure decreased
most of the inflammatory cytokines assessed in women in
the early stages of menopause, ageing was associated with
estrogen’s effect on the switch from anti-inflammatory to
proinflammatory in the arteries of women who had started
menopause at least 10 years prior [89], suggesting that the
effect of estrogens is timing-dependent. In addition, estradiol
attenuates inflammatory responses in macrophages and
VSMCs derived from young but not old female mice [90],
suggesting that the anti-inflammatory properties of estradiol
are lost as ageing continues.
As mentioned above, the relative expression of specific
ERs has been related to the role of estrogens in vascular age-
ing and it has postulated that a change in the balance
between ERα and ERβ could explain the lack of vascular
protection provided by estrogen. In that sense, an age-
dependent increase in ERβ but not in ERα expression was
observed in uterine arteries from postmenopausal women
[89], thus producing this increased ERβ/ERα ratio. In young
ovariectomized mice, although estrogen supplementation
downregulated ERs, it did not alter the ERβ/ERα ratio in
endothelium or smooth muscle; in contrast, the ERβ/ERα
ratio increased after estrogen treatment in aged female mice
[91]. Finally, decreased ERα expression was also reported in
aged compared to young macrophages [90].
4. Sex and Age Influence in miRNA Expression
Sex and age differences in miRNA expression profiles have
been described in different tissues [92–94], providing evi-
dence for the role of sex hormones and ageing in miRNA
regulation. Sex differences are usually attributed to the mod-
ulation of estrogen transcriptional activity mediated by ERs,
and so differences in the miRNA profiles obtained from ER
+ and ER− breast cancer cells [95, 96] are related to the loss
of ER binding sites located near the miRNA sequences which
are found less abundance in ER− breast cancer cells [96]. At
the vascular cell level, ER binding sites were located within
the regulatory region of estradiol-regulated miRNAs [97, 98].
Sex-biased miRNAs are also driven by the expression of
miRNAs located in sex chromosomes. It is worth noting that,
according to miRBase (March 2018; http://www.mirbase
.org), 118 miRNAs are located on the human X chromosome
but only 4 were present on the Y chromosome. Most X chro-
mosome miRNAs are involved in X chromosome inactiva-
tion which occurs early in development to compensate for
gene dosage imbalances between the sexes [99]. In this
respect, the mosaicism resulting from X chromosome inacti-
vation may be involved in some of the increased susceptibil-
ity to inflammatory and autoimmune diseases experienced
by women [100]. Regarding X-linked miRNAs and cardio-
vascular diseases, Florijn et al. recently reviewed the implica-
tion of miRNAs in women with heart failure with a preservedejection fraction and concluded that estradiol-induced miR-
NAs are protective while X-linked miRNAs are associated
with deleterious effects [101]. Conversely, both age and estro-
gens can modulate miRNA profiles by regulating miRNA
biosynthesis pathways.
miRNA production is a two-step process involving
nuclear cropping and cytosolic dicing; mature miRNAs are
derived from a stem-loop transcript (also known as pri-
miRNA) which is cleaved in the nucleus by a microprocessor
complex—comprising the RNase III, Drosha, and DiGeorge
syndrome critical region 8 (DGCR8)—into a small hairpin-
shaped RNA (pre-miRNA) which is transported to the cyto-
plasm through exportin 5 where maturation can be com-
pleted. In a second processing step, the pre-miRNA is
cleaved—by the RNase III, Dicer—into approximately 22-nt
miRNAduplexes. One strand from themiRNAduplex usually
remains as amaturemiRNA,while the other is generally selec-
tively degraded via a thermodynamic stability-dependent
process. Finally, mature miRNAs are loaded into Argonaute
(AGO) proteins to form, along with other components, the
RNA-induced silencing complex (RISC) effector. The final
miRNAs function as a guide by base pairing—usually at the
3′-untranslated region (UTR)—to target mRNAs, and AGO
proteins recruit factors that induce the translational repres-
sion of these mRNAs [102].
With ageing, molecules implicated in miRNA expression
machinery become downregulated, thus suggesting that
miRNA expression is age-dependent: an effect also described
in old versus young peripheral blood mononuclear cells
[103]. The same study showed that the expression of miRNA
biogenesis molecules is depressed in octogenarians compared
with centenarians, which may indicate that greater expres-
sion of miRNA production components is associated with
extraordinarily successful ageing. At the vascular level,
Dicer1 is downregulated in old versus young cerebral vessels
isolated from rats, which these authors associated with
altered miRNA expression profiles and impaired endothelial
function [104]. Indeed, the impaired vascular formation
observed in Dicer1 knockout mice was one of the first pieces
of evidence that related miRNA biosynthesis to vascular
function [105]. In endothelial cells, Dicer1 depletion revealed
that miRNA processing is essential for correct endothelial
gene expression and function, including proliferation and
angiogenesis [106, 107].
The role of estrogen in regulating key miRNA production
molecules has been reviewed elsewhere [108], and of note,
most studies relating estrogen activity and miRNA biosyn-
thesis have been performed in reproductive organs. Differ-
ences in key miRNA-processing genes have been observed
between ER+ and ER− breast cancer cells [95, 109]; specifi-
cally, the expression of Dicer1, DGCR8, and Drosha was
higher, and that of Ago-2 was lower in ER+ breast tumors
[110]. Nevertheless, among the miRNA processing genes,
only Dicer1 contains an ERα binding site in its regulatory
region [110]. Furthermore, a regulatory ER-Drosha interac-
tion has been reported in breast cancer cells [111] and an
estrogen-dependent increase in exportin-5 expression was
reported in the mouse uteri [112]. At the vascular level, global
transcriptomic analysis data of endothelial cells treated with
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sis pathway genes [113]. Specifically, DGCR8 upregulation
and Dicer1 and Ago-2 downregulation were observed in
estradiol-treated cells, suggesting that estrogens regulate
endothelial miRNA production machinery [113].
5. Estrogen-Regulated miRNAs and
Vascular Ageing
As described above, sex- and age-specific miRNA profiles are
the result of transcriptomic changes, sex chromosome
expression, and miRNA biosynthesis regulation. In addition,
findings in women receiving HRT have provided insights
into the roles of estrogen-associated miRNAs during ageing
in different tissues (Table 1). Changes in the miRNA expres-
sion profile in bone tissue from both ovariectomy-induced
osteoporotic mice and postmenopausal women have been
described [114, 115]. Specifically, miR-127 andmiR-136 have
been described as negative regulators of bone mass [114],
whereas the expression level of miR-30b-5p has been pro-
posed as a suitable serum biomarker for osteoporosis and
osteopenia in postmenopausal women [115]. Furthermore,
Olivieri et al. reported that estrogen has a positive impact
in postmenopausal women using HRT as a result of skeletal
muscle changes mediated via the suppression of miR-182
and miR-223 expression. These miRNAs are implicated in
regulating the insulin/insulin-like growth factor (IGF-1)
pathway which is key in muscle mass homeostasis [116].
Moreover, changes in the miRNA expression profile in adi-
pose tissue have recently been described in association with
HRT [117]. Specifically, miR-19a-3p was identified as being
HRT-sensitive in adipose tissue because its levels in HRT-
treated postmenopausal women were similar to those
observed in premenopausal women and were higher than
in postmenopausal women who did not use HRT. ESR1 is a
miR-19a-3p target [118] and, thus, could be involved in the
changes in ERα observed in adipose tissue during ageing
[119] and may underlie the adverse age-related alterations
in adipose metabolism in women [120].
In addition to tissue-specific miRNA expression,
estrogen-dependent regulation in circulating miRNAs has
also been described both in ovariectomized animals [115]
and postmenopausal women receiving HRT [121, 122]. The
studies in women were performed in monozygotic twin pairs
and showed an association between changes in serum inflam-
matory markers and inflammatory-related miR-21 and miR-
146a [121]. There were also alterations in the miRNAs
included in exosomes in postmenopausal women using
HRT [122], suggesting that changes in circulating miRNAs
are associated with estradiol levels. Therefore, estrogen-
sensitive miRNAs could be used both as therapeutic targets
and as potential biomarkers for characteristic physiological
alterations related to female ageing, such as osteoporosis, sar-
copenia, changes in body fat homeostasis, and ageing-
associated inflammation.
Specific miRNAs implicated in cardiac and vascular age-
ing have been reviewed in depth elsewhere [17, 18]. In addi-
tion, we have addressed the role of estrogen-regulated
miRNAs in cardiovascular function in a recent review[113]. However, how miRNAs are implicated in the action
of estrogen in the vasculature during ageing remains to be
elucidated. In the following paragraphs, we describe the
involvement of specific miRNAs in the effect of estrogens
during female vascular ageing, and Tables 2 and 3 summarize
the main circulating and tissue-specific miRNAs involved in
female vascular ageing, respectively.
miR-126 is highly expressed in vascularized tissues and
was the first miRNA reported as being crucial in endothelial
biology. It is located within an intron of the epidermal
growth factor-like domain multiple 7 (EGFL7) gene which
is mostly expressed in endothelium and is involved in vascu-
lar angiogenesis. This miR-126 is involved in vascular integ-
rity and angiogenesis [123, 124] but also appears to modulate
immune cell adhesion and VSMC function [125, 126]. Serum
levels of estradiol are positively associated with miR-126-3p
expression throughout the menstrual cycle; estradiol also
increases miR-126-3p expression in cultured endothelial cells
[127] but decreases it in lymphocytes [128], suggesting that it
has a cell-specific effect on miR-126-3p expression. In endo-
thelial cells, estradiol-dependent miR-126-3p suppresses the
miR-126-3p targets, Spred1 and VCAM1, and is related to
an increase in cell migration, proliferation, and tube forma-
tion, while decreases monocyte adhesion [127]. Moreover,
miR-126-3p is also implicated in the estradiol-dependent
reduction of plaque size in ApoE−/− mice [127]. Indeed,
miR-126 released by endothelial cells controls VSMC behav-
ior [126] and limits neointimal formation [129]. Given that
circulating miR-126 expression is altered in several cardio-
vascular diseases [130], these findings suggest that estradiol’s
vasculoprotective and antiatherogenic properties could be
partly mediated by miR-126. Circulating miR-126 is down-
regulated in different cardiovascular diseases [131, 132],
although its relationship with and ageing is contradictory;
compared to young individuals, miR-126 was downregulated
in blood samples from centenarians [133], but miR-126-5p
expression in circulating exosomes was higher in postmeno-
pausal versus premenopausal women [122] and miR-126-3p
was increased in senescent endothelial cells in vitro and in
plasma collected from healthy older patients [134]. Olivieri
et al. hypothesize that this miR-126 upregulation is a com-
pensatory mechanism to reduce cell dysfunction during nor-
mal ageing.
miR-106 expression is sex-specific. miR-106a/b were
among the sex-specific miRNAs regulated via ERβ in a
murine model of pressure overload-induced cardiac fibrosis
mediated by regulation of specific profibrotic MAPK signal-
ing repressors [135], evidence that miR-106 may be involved
in sex-related differences in this pathology. In estradiol-
treated rat cardiac fibroblasts, miR-106b expression is
decreased in both female and male cells while miR-106a
expression is downregulated in female cells but upregulated
in male cells [135]; furthermore, miR-106b was downregu-
lated in cultured VSMCs treated with estradiol [97], suggest-
ing that estradiol has sex-specific effects in downregulating
miR-106b. In contrast, miR-106b-5p expression was lower
in postmenopausal women not using HRT compared to
those that did use HRT [122], suggesting that estrogens have
the opposite effect on miR-106 expression during ageing. The
Table 1:3 HRT-sensitive miRNAs involved in age-associated diseases in postmenopausal women; miRNAs related to disease and the tissue
sample types used in the study are listed and the miRNA-related function and specific miRNA targets are shown.
Disease (tissue) miRNA Function (targets) References
Osteoporosis (bone) miR-127 and miR-136
Regulation of bone mass
(COL1, ALP, RUNX2, and OC)
[114]
Osteoporosis (serum) miR-30b-5p Biomarker [115]
Sarcopenia (skeletal muscle) miR-182 and miR-223
Regulation of the insulin/IGF-1 pathway
(IGF-1R and FOXO3A)
[116]
Obesity (adipose tissue) miR-19a-3p
Adipocyte cell fate, death, and proliferation
(ESR1, AKT1, BCL2, BRAF, and CCND1)
[117]
Inflammageing (Serum) miR-21 and miR-146a Biomarker [121]
Table 2: Circulating miRNAs associated with estrogen levels and/or ageing.
miRNA Ageing Estrogen Sample/model References
miR-126 − Blood samples from centenarians [133]
miR-126-3p − Plasma from healthy people [134]
miR-126-3p + Serum from healthy women [127]
miR-126-5p + Serum exosomes from postmenopausal women [122]
miR-106b − Serum from older women [137]
miR-106b-5p + Serum from HRT-treated postmenopausal women [122]
miR-30b-5p + Serum samples from ovariectomized rats [115]
miR-23a − Serum from female rats [166]
miR-144 + Serum from HRT-treated postmenopausal women [122]
miR-146a − Serum from HRT-treated postmenopausal women [121]
miR-21
+ Plasma from elderly people [183]
+ − Serum from HRT-treated and non-HRT-treated postmenopausal women [121]
Positive or negative associations with ageing and estrogens are represented, and the sample type or model used in each study is shown. HRT: hormone
replacement therapy.
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licative endothelial cell ageing [136] and in serum from older
women [137]. In endothelial cells treated with tumor necro-
sis factor alpha (TNF-α), miR-106b-5p exerts antiapoptotic
effects by repressing phosphatase and tensin homolog
(PTEN) caspase activity [138], and in a rat cardiomyoblast
cell line exposed to hypoxia, it suppresses apoptosis by
directly targeting p21 [139], findings that concur with the
known repressive effects of estrogens on PTEN and apopto-
sis [140, 141].
In miR-221/222, the cluster containing the miR-221/222
gene is located on the X chromosome and is regulated both
by ageing and estrogen-mediated mechanisms; serum levels
of miR-222 increase with ageing in both males and females
[137]. Moreover, in human aortic endothelial cells, miR-
221/222 expression was upregulated in an in vitro replicative
senescence model and correlated with decreased eNOS
expression and activity [142]. Moreover, endothelial cells
transfected with miR-221 and miR-222 showed reduced
eNOS protein levels [106]. However, eNOS 3′-UTR mRNA
does not contain a target sequence for miR-221 or miR-
222, suggesting that an intermediate mechanism may be
responsible for this miR-221/222-mediated eNOS repression.
Indeed, miR-222 was among the sex-dimorphic miRNAsidentified in mice heart tissues and isolated cardiomyocytes;
miR-222 inhibits eNOS expression by directly targeting ets-
1 mRNA [143], an upstream eNOS regulator. These results
indicate that miR-222 plays an important role in heart func-
tion that may be sex-specific in terms of providing female
cardioprotection [144]. Conversely, miR-221/222 regulate
and are regulated by ERα activity [145], suggesting the pres-
ence of a negative regulatory loop between them. One
hypothesis is that before menopause, estrogen-ERα activity
limits miR-221/222 levels, thus maintaining eNOS expres-
sion and cardioprotection. However, ageing and menopause
increase miR-221/222 levels and decrease ERα and eNOS
expression by downregulating ets-1. In addition, miR-221/
222 are strongly upregulated in the carotid artery in a bal-
loon injury model and their depletion suppresses VSMC
proliferation and neointimal formation [146] which may
be because estrogens attenuate neointimal formation after
vascular damage [86].
miR-143/145 activity appears to be essential in regulating
VSMCs to prevent the ageing-related switch from a contrac-
tile to synthetic-proliferative VSMC phenotype [147], and
miR-143/145 dysregulation has been described in different
cardiovascular pathologies. These miRNAs maintain VSMCs
in a quiescent state and inhibit proliferation by regulating
Table 3: Cardiovascular-related miRNAs associated with estrogens and ageing.
miRNA Ageing Estrogen Tissue/cell Function (target) References
miR-126
+ Endothelial cells
Endothelial proliferation, migration, tube formation, and
monocyte adhesion (Spred1 and VCAM1)
[127]
+ Endothelial cells Senescence-associated compensatory mechanism (Spred1) [134]
− Lymphocytes Unexplored [128]
miR-106
− Endothelial cells Unexplored (p21/CDKN1A) [136]
− VSMCs Unexplored [97]
− Cardiac fibroblasts Regulation of cardiac fibrosis via ERβ (Rasa1 and Rasa2) [135]
miR-221/222
+ Endothelial cells Suppression of eNOS and pSer1177-eNOS [142]
+ Aorta Unexplored [173]
f<m Cardiomyocytes Regulation of eNOS expression (Ets-1) [143]
miR-143/145 + PASMCs SMC and EC cell migratory phenotypes [150]
miR-30b-5p + Endothelial cells Unexplored [98]
miR-23a
+ Endothelial cells [164]
+ Fibroblasts Telomere dysfunction (TRF2) [165]
− Myocardium Loss of cardiac gap junctions (CX43) [166]
− Cardiomyocytes Ventricular remodeling (PGC1) [169]
miR-203
+ Aortic SMCs VSMC stiffness (Src and ERK) [173]
+ Aortic SMCs Inhibition of VSMC proliferation (Abl1 and p63) [97]
miR-144 + Endothelial cells Antioxidant response (NRF2) [176]
miR-146a
+ Endothelial cells Proinflammatory status marker (IRAK1) [180]
− Endothelial cells Senescence-like phenotype (NOX4) [181]
− Lymphocytes Regulation of LPS-induced IFN-γ (unknown) [128]
miR-21
+ Heart Unexplored [182]
+ Endothelial cells
Decrease angiogenesis and cell proliferation (NFIB and
CDC25A)
[164]
− Endothelial cells Antiproliferative effect (associated with PTEN and p27) [142]
− Cardiac fibroblasts Regulation of cardiac fibrosis (SPRY1, Rasa1, and Rasa2) [135]
miR-34
+ Aorta Unexplored [173]
+ Aorta/VSMCs Promotes VSMC senescence and inflammation (SIRT1) [192]
+ Endothelial cells Cell growth arrest and senescence (SIRT1) [191]
+ Cardiomyocytes Age-associated cell death (PNUTS/PPP1R10) [190]
− Endothelial cells Regulation of eNOS expression (SIRT1) [194]
miR-22
+ Cardiac fibroblasts




Inhibition of cardiac autophagy and cell hypertrophy
(Akt3, Hdac6, and Ppara)
[197]
− Cardiomyocytes/myocardium Increased antioxidant defense (SP1) [198]
miR-125
+ Endothelial cells Impaired angiogenesis (RTEF1) [202]
+ Macrophages Inhibitor of NF-κB signaling (κB-Ras2) [201]
− Lymphocytes Unexplored [128]
Positive or negative associations with ageing and estrogens are represented, and the tissue or cell type used, miRNA-related function, and described miRNA
target are shown. Sex differences are indicated where appropriate (f: female; m: male). SMC: smooth muscle cell; VSMC: vascular SMC; PASMC: pulmonary
artery SMC.
7Oxidative Medicine and Cellular Longevityseveral targets, including angiotensin-converting enzyme
[148] which modulates vascular contractibility. It has been
reported that miR-143/145 are delivered from endothelial
cells to VSMCs where they repress genes associated with
dedifferentiation [149] such as myocardin, ELK1, and
KLF4. Estradiol induces miR-143/145 expression in pulmo-
nary artery smooth muscle cells (PASMCs) via specific ERbinding sites located in their promoter regions [150]. More-
over, estradiol-treated PASMCs secrete exosomes enriched
in miR-143/145 which regulate VSMC-endothelium cross-
talk in pulmonary arterial hypertension, regulating vascu-
lar remodeling [150] and perhaps playing a role in exerting
estrogen-mediated effects on the VSMC phenotype.
Although no specific studies on miR-143/145 expression in
8 Oxidative Medicine and Cellular Longevitycardiovascular cells during ageing have been undertaken,
miR-145 expression negatively correlates with age in patients
with coronary artery disease [151].
miR-30 is estrogen-sensitive and its expression is related
to estrogen levels in different tissues [110, 152, 153]; indeed,
ER binding sites have been identified upstream of the miR-
30 transcription start site [96, 98]. Reinforcing the role of
estrogens in regulating miR-30b-5p, its expression was
downregulated in serum from ovariectomized rats and from
postmenopausal osteoporotic women [115] and miR-30b-5p
was the most upregulated miRNA in endothelial cells treated
with estradiol [98]. There is also evidence that miR-30b
family members are involved in cardiovascular diseases
because their expression is decreased in vascular injury
[154], inversely correlates with blood pressure parameters
[155], and inhibits VSMC proliferation and neointimal for-
mation [154]. However, the role of miR-30 family members
in myocardial infarction remains controversial [156–158].
In endothelial cells, miR-30 is implicated in angiogenic pro-
cesses [159], has anti-inflammatory effects by decreasing
angiopoietin 2-induced VCAM1 expression [160], and
inhibits apoptosis in human coronary artery endothelial cells
[161]. In this regard, it is noteworthy that estradiol also has
proangiogenic, anti-inflammatory, and antiapoptotic proper-
ties in response to vascular injury [162].
miR-23a belongs to the miR-23-24-27 cluster which has
been implicated in angiogenic processes and cardiac function
[163] and also has ERα binding sites in its regulatory regions.
Members of this cluster are upregulated during endothelial
replicative ageing [164], and miR-23a overexpression reduces
telomere length and induces senescence in human fibroblasts
[165]. In serum and myocardium in rats, miR-23a expression
inversely correlates with estradiol levels and regulated
connexin-43 in a menopausal rat model [166]. In postmeno-
pausal rats, estrogen supplementation rescued blockage of
cardiac conduction by decreasing miR-23a, thus revealing
potential mechanisms involved in postmenopause-related
arrhythmias [167]. Moreover, miR-23a may affect cardiac
hypertrophic processes [168]: its increased expression in
estrogen-deficient ovariectomized mice causes mitochondrial
compromise and ventricular remodeling by directly repres-
sing peroxisome proliferator-activated receptor-γ coactivator
1-α (PGC-1α) expression in cardiomyocytes [169]. Moreover,
miR-27 is upregulated in senescent endothelial cells [164]
and in circulating exosomes in premenopausal versus post-
menopausal women [122]. This miRNA has been implicated
in LDLR expression [170], angiogenic processes [107], and
may be a biomarker for progression in asymptomatic carotid
stenosis [171].
miR-203 is upregulated in estradiol-treated mouse aortic
VSMCs [97]; miR-203 induction is regulated through an
ERα-dependent mechanism and its inhibition abolishes
estradiol-mediated inhibition of VSMC proliferation, sug-
gesting a role for miR-203 in the antiproliferative effect of
estrogens [97]. In addition, miR-203 can downregulate ERα
by direct targeting [172], suggesting its involvement in a reg-
ulatory loop. Conversely, increased miR-203 expression
found in aged aorta has recently been associated with age-
related VSMC stiffness [173].In miR-144, circulating estradiol concentrations were
positively correlated with miR-144-5p in a study of women
receiving HRT [122], and in the same study, miR-144-5p
was inversely correlated with TNF-α levels, together suggest-
ing it has an estrogen-mediated role in regulating inflamma-
tory processes. Indeed, miR-144 is implicated in targeting
superoxide-related proteins such as COX-2 [174] and the
NADPH oxidase component Rac1 [175]. Conversely, miR-
144 is upregulated in cerebral microvascular endothelial cells
from aged mice, and its inhibition upregulates the antioxi-
dant transcription factor NRF2 [176]; miR-144 is also
involved in lipid metabolism by repressing the expression
of cholesterol efflux regulatory protein ABCA1 [177], while
the ABCA1 inducer, nuclear factor LXR, increases miR-144
expression, suggesting the presence of a negative regulatory
loop. Furthermore, induced LXR and ABCA1 expression
has been related to an estradiol-dependent reduction of lipid
accumulation in macrophages and VSMCs [58, 59] suggest-
ing that estrogen tightly regulates lipid content via this
miRNA-mediated pathway. Finally, the effect of estrogen
on cholesterol efflux is modified by age [178] and this may
be related with the dysregulation of miR-144 expression dur-
ing ageing.
miR-146a is one of the key miRNAs associated with vas-
cular inflammation; it regulates endothelial activation by tar-
geting upstream NF-κB pathway regulators such as TNF
receptor associated factor (TRAF) 6 and IL-1 receptor associ-
ated kinase (IRAK1) [179] and is described as a marker of
senescence-associated proinflammatory status in endothelial
cells [180]. In a replicative endothelial cell model, miR-146a
downregulation may have caused endothelial senescence by
increasing the expression of its direct target, NOX4 [181].
The relationship between miR-146a expression and estrogen
has previously reported since circulating miR-146a expres-
sion was different between HRT-treated and nontreated
postmenopausal genetically identical twins [121]. In addi-
tion, estradiol inhibition of miR-146a expression may be a
key regulator of lipopolysaccharide-induced interferon-
gamma (IFN-γ) expression in lymphocytes [128].
miR-21 expression is also related to estrogens and ageing;
increased miR-21 levels have been found in aged heart tissues
[182], in senescent vascular cells [164], and in blood samples
in elderly people [183]. However, conversely, repression of
miR-21 in senescent human aortic endothelial cells seems
to increase the expression of antiproliferative and proapopto-
tic molecules [142] and may represent a diagnostic bio-
marker for acute myocardial infarction [184]. In cardiac
fibroblasts, miR-21 action is implicated in heart hypertrophy
by activating MAPK pathways [185], proinflammatory
responses in endothelium under oscillatory shear stress
[186], and VSMC proliferation after vascular injury [187].
However, the cardiovascular effects of estrogens attenuate
these responses; indeed, estradiol downregulates miR-21 by
binding to ERs in its promoter region [188] and miR-21
expression in postmenopausal women using HRT was lower
than their twin sisters who did not use HRT [121]. Finally, in
a murine model of pressure overload-induced cardiac fibro-
sis, miR-21 was among sex-specific miRNAs regulated by






























Figure 1: Estrogen-sensitive miRNAs associated with cardiovascular ageing are classified according to their role in the three main
mechanisms leading to cardiovascular ageing: cardiovascular remodeling, endothelial dysfunction, and inflammation. (↓) and (↑) indicates
increased or decreased expression in cardiovascular tissues during ageing, respectively. Role of estrogens on the expression of represented
miRNA is also represented; (−) and (+) indicates negative or positive regulation, respectively. Controversial findings dependent on
expression in different tissues/cells are indicated as (↓↑) and (−/+).
9Oxidative Medicine and Cellular Longevitycardiac fibroblasts [135] which may explain sex-dependent
differences in cardiac remodeling [189].
miR-34 is part of a well-described family of ageing-
associated miRNAs related to cardiomyocyte apoptosis
[190] and vascular cell senescence [191, 192]. The expression
of miR-34 is elevated in old versus young aorta [173] as well
as during ageing and in cardiac pathologies; however, inhibi-
tion of the miR-34 family improves heart function [193].
Moreover, miR-34 is influenced by sex and estrogens; miR-
34b-3p expression is higher in male rather than female
mouse hearts [143] and therapeutic inhibition of miR-34
improves cardiac function [190, 193]. Furthermore, estradiol
exposure decreases miR-34a expression in cultured endothe-
lial cells [194] and is associated with SIRT1-dependent regu-
lation of eNOS. Moreover, blockage of miR-34a expression
was more effective in females than in males in a murine
model of moderate dilated cardiomyopathy [195], highlight-
ing the importance of studying sex-related differences in
miRNA-based therapies.
miR-22 is upregulated in aged hearts [196, 197] and con-
tributes to cardiac hypertrophy by promoting senescence
and migratory activity in cardiac fibroblasts [196] and by
inhibiting autophagy in cardiomyocytes [197]. Estradiol also
appears to decrease miR-22 expression in primary cardio-
myocytes via ERα-mediated mechanisms [198]. In addition,
miR-22 downregulation increases oxidative defense by
increasing expression of its direct target, Sp1 [198]: a regula-
tory pathway that may explain estradiol-mediated cardio-
protection. A reciprocal feedback loop between ERα and
miR-22 may be involved in fine-tuning the regulation of
estrogen action by posttranscriptionally controlling ERα
expression [199].miR-125 is part of a family of miRNAs which are mainly
associated with the activation of inflammatory cells. In mac-
rophages exposed to lipopolysaccharide (LPS), miR-125a is
upregulated [200] and miR-125b is downregulated [201].
However, more studies are needed to understand their role
in activating or inhibiting inflammatory processes. The reg-
ulation of some miR-125 family members is estrogen-
dependent: estradiol inhibits NF-κB activity by restoring
downregulated miR-125b expression in LPS-stimulated
macrophages [201] and both miR-125a and miR-125b are
downregulated in lymphocytes exposed to estradiol [128].
Moreover, miR-125 activity is also associated with angiogen-
esis during ageing: miR-125a-5p expression is increased in
endothelial cells from aged mice and is involved in impaired
angiogenesis [202].
6. Conclusion
The role of sex hormones in cardiovascular physiology has
been extensively studied and has been proposed as the cause
of the reported sex-related differences in cardiovascular dis-
eases. Vasodilation, inflammation inhibition, and the action
of antioxidants have all been attributed to the effect that
estrogens exert on the cardiovascular system. However, the
effects that estrogens have on the heart and vascular tissues
are themselves modified by ageing. Estrogens modify cardio-
vascular function by modulating gene expression, and in this
sense, miRNAs have emerged as a new regulatory mecha-
nism of both physiological and pathological processes
because they regulate gene expression profiles at the post-
transcriptional level (Figure 1). Studies onmiRNAs have pro-
vided insights into cardiovascular function, age-associated
4
10 Oxidative Medicine and Cellular Longevityphysiological changes, and cardiovascular pathologies. How-
ever, information about the role of miRNAs in estrogen-
dependent processes in cardiovascular ageing is still scarce.
Therefore, basic research to analyze sex-specific miRNA reg-
ulation can help us to understand differences in cardiovascu-
lar diseases between men and women. It may be possible to
translate this new knowledge into clinical research, using
miRNAs as potential tools for giving diagnoses and/or prog-
noses, as affordable and noninvasive biomarkers, and as a
therapeutic tool for regulating (silencing or increasing)
miRNA levels. Thus, future perspectives in miRNA-based
therapies should consider the importance of sex-related
differences in vascular ageing.
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